Pharmacologic Treatment of Eosinophilic Esophagitis: An Update.

Alain M Schoepfer, Alex Straumann, Ekaterina Safroneeva

Journal: Gastrointestinal endoscopy clinics of North America 2018;28(1):77-88

PMID: 29129301

Abstract

Eosinophilic esophagitis (EoE) is defined as a chronic, immune-medicated or antigen-mediated, esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Food allergens are identified in most patients. Treatment strategies include elimination diets, drugs, and esophageal dilation. This article focuses on pharmacologic treatment. Currently, there is no pharmacologic treatment that has been approved by regulatory authorities. Established pharmacologic options to treat EoE include proton pump inhibitors and swallowed topical steroids. Several biologic therapies are currently under evaluation and some of them have shown promising results in improving biologic endpoints and patient-reported outcomes.

Copyright © 2017 Elsevier Inc. All rights reserved.

Address: Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV), Rue de Bugnon 44, 07/2409, Lausanne 1011, Switzerland. Electronic address: [email protected].; Swiss EoE Clinic, Römerstrasse 7, 4600 Olten, Switzerland; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland.; Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.